Detailed information on the current drug pipeline. This report provides insight into the pipeline status of lupus drugs by company and by stage as well as a summary of the latest news and developments in this area.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of crohn disease drugs by company and by stage as well as a summary of the latest news and developments in this area.

A new report examining how the competitive dynamics of major pharma companies will influence the market positions of products and shape the direction of future global autoimmunology.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of arthritis drugs by company and by stage as well as a summary of the latest news and developments in this area.

Key issues in Systemic Lupus Erythematosus (SLE) are discussed, including opportunities and threats in the market and analysis of novel therapies in the developmental pipeline.

Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major marke

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of inflammation drugs by company and by stage as well as a summary of the latest news and developments in this area.

In a market believed to approach 5 million people in the leading pharma markets, the market for rheumatic anti-inflammatory drugs is both profitable and set to increase due to new launches.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of transplant rejection or transplantation drugs by company and by stage as well as a summary of the latest news and developments in this area.

Current, pipeline and emerging drugs for the treatment of Crohn’s Disease

Asthma is managed using a step-wise approach, with bronchodilators to relieve symptoms of airflow limitation and controller medications to target underlying inflammation.

The autoimmune disease market will be rapidly growing due to a high number of competitive brands currently on the market and a full pipeline. Company strategies include expanding the treatment algorithm by pursuing approval for ’early’ dise

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of rheumatoid arthritis drugs by company and by stage as well as a summary of the latest news and developments in this area.

The global Rheumatoid Arthritis (RA) market has experienced extraordinary growth over the last decade. This market valued at $4.14 billion in 2004, shows no hint of decline. The explosion in new disease modifying drugs since the late 1990`s has resulte

Juvenile arthritis is the next indication due for approval for blockbuster biologic therapies Remicade (infliximab) and Humira (adalimumab). Pediatric rheumatology is a growing specialty that offers high unmet need in terms of effective well-tested tre

COPD is a deadly disease of the elderly, with patients suffering years of progressive discomfort and disability with no pharmacological interventions able to slow the progressive decline in lung function. A large, increasing patient population demands

There is a positive outlook for the respiratory market over the next five years, which will experience a sustained period of growth driven by the expansion of sales in existing classes, the launch of major new products, and the results from several lan

According to the US National Heart, Lung, and Blood Institute and the European Respiratory Society, the annual cost of asthma is estimated to be $16.1 billion in the US and $16.3 billion in the EU. Over 41.5 million people, equivalent to the population

The treatment of Rheumatoid Arthritis (RA) has been rapidly evolving over the last decade. Currently, the newer targeted biologic therapies against specific molecules involved in the pathogenesis of RA reduce side-effects, but cheaper traditional thera

Psoriasis is a non-life threatening but highly debilitating disease that currently has no cure. Traditional treatments often either lack efficacy or are effective but have very poor side-effect profiles, limiting them to use in severe disease only. How

The asthma, COPD and allergic rhinitis global market was $25.5 billion in 2004, with five brands selling over $1.0 billion. While a number of moderately successful launches are expected within the next five years, companies are seeking novel combinatio

This unique product offering provides an analysis of changing market conditions and strategic future outlook using the gold standard IMS Health sales data and Business Insights ’ expert analysis, an unrivalled source of pharmaceutical intelligenc